This strategy is of special interest in Her-2-positive and TNBC breast cancer patients, which globally represent less than 20% of the total breast cancer diagnoses and associate worse prognosis but also are the best responders to neoadjuvant chemotherapy. Here, ERBB2 is linked to breast cancer.